These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
775 related articles for article (PubMed ID: 26500061)
1. PI3K-p110α mediates resistance to HER2-targeted therapy in HER2+, PTEN-deficient breast cancers. Wang Q; Liu P; Spangle JM; Von T; Roberts TM; Lin NU; Krop IE; Winer EP; Zhao JJ Oncogene; 2016 Jul; 35(27):3607-12. PubMed ID: 26500061 [TBL] [Abstract][Full Text] [Related]
2. Addition of the p110α inhibitor BYL719 overcomes targeted therapy resistance in cells from Her2-positive-PTEN-loss breast cancer. Zhang C; Xu B; Liu P Tumour Biol; 2016 Nov; 37(11):14831-14839. PubMed ID: 27639383 [TBL] [Abstract][Full Text] [Related]
3. Combined Inhibition of Both p110α and p110β Isoforms of Phosphatidylinositol 3-Kinase Is Required for Sustained Therapeutic Effect in PTEN-Deficient, ER Hosford SR; Dillon LM; Bouley SJ; Rosati R; Yang W; Chen VS; Demidenko E; Morra RP; Miller TW Clin Cancer Res; 2017 Jun; 23(11):2795-2805. PubMed ID: 27903677 [No Abstract] [Full Text] [Related]
4. Enhanced PI3K p110α signaling confers acquired lapatinib resistance that can be effectively reversed by a p110α-selective PI3K inhibitor. Brady SW; Zhang J; Seok D; Wang H; Yu D Mol Cancer Ther; 2014 Jan; 13(1):60-70. PubMed ID: 24249715 [TBL] [Abstract][Full Text] [Related]
5. Conditional loss of ErbB3 delays mammary gland hyperplasia induced by mutant PIK3CA without affecting mammary tumor latency, gene expression, or signaling. Young CD; Pfefferle AD; Owens P; Kuba MG; Rexer BN; Balko JM; Sánchez V; Cheng H; Perou CM; Zhao JJ; Cook RS; Arteaga CL Cancer Res; 2013 Jul; 73(13):4075-85. PubMed ID: 23633485 [TBL] [Abstract][Full Text] [Related]
6. Direct inhibition of PI3K in combination with dual HER2 inhibitors is required for optimal antitumor activity in HER2+ breast cancer cells. Rexer BN; Chanthaphaychith S; Dahlman K; Arteaga CL Breast Cancer Res; 2014 Jan; 16(1):R9. PubMed ID: 24451154 [TBL] [Abstract][Full Text] [Related]
7. A preclinical evaluation of the PI3K alpha/delta dominant inhibitor BAY 80-6946 in HER2-positive breast cancer models with acquired resistance to the HER2-targeted therapies trastuzumab and lapatinib. Elster N; Cremona M; Morgan C; Toomey S; Carr A; O'Grady A; Hennessy BT; Eustace AJ Breast Cancer Res Treat; 2015 Jan; 149(2):373-83. PubMed ID: 25528022 [TBL] [Abstract][Full Text] [Related]
8. Sensitivity to targeted therapy differs between HER2-amplified breast cancer cells harboring kinase and helical domain mutations in PIK3CA. Garay JP; Smith R; Devlin K; Hollern DP; Liby T; Liu M; Boddapati S; Watson SS; Esch A; Zheng T; Thompson W; Babcock D; Kwon S; Chin K; Heiser L; Gray JW; Korkola JE Breast Cancer Res; 2021 Aug; 23(1):81. PubMed ID: 34344439 [TBL] [Abstract][Full Text] [Related]
9. PTEN-deficient cancers depend on PIK3CB. Wee S; Wiederschain D; Maira SM; Loo A; Miller C; deBeaumont R; Stegmeier F; Yao YM; Lengauer C Proc Natl Acad Sci U S A; 2008 Sep; 105(35):13057-62. PubMed ID: 18755892 [TBL] [Abstract][Full Text] [Related]
10. Features of the reversible sensitivity-resistance transition in PI3K/PTEN/AKT signalling network after HER2 inhibition. Goltsov A; Faratian D; Langdon SP; Mullen P; Harrison DJ; Bown J Cell Signal; 2012 Feb; 24(2):493-504. PubMed ID: 21996585 [TBL] [Abstract][Full Text] [Related]
11. PI3K PROTAC overcomes the lapatinib resistance in PIK3CA-mutant HER2 positive breast cancer. Zhang H; Zhang L; He Y; Jiang D; Sun J; Luo Q; Liang H; Wang T; Li F; Tang Y; Yang Z; Liu W; Rao Y; Chen C Cancer Lett; 2024 Aug; 598():217112. PubMed ID: 38986734 [TBL] [Abstract][Full Text] [Related]
12. Expression of CD24 is associated with HER2 expression and supports HER2-Akt signaling in HER2-positive breast cancer cells. Hosonaga M; Arima Y; Sugihara E; Kohno N; Saya H Cancer Sci; 2014 Jul; 105(7):779-87. PubMed ID: 24754246 [TBL] [Abstract][Full Text] [Related]
13. PI3K isoform dependence of PTEN-deficient tumors can be altered by the genetic context. Schmit F; Utermark T; Zhang S; Wang Q; Von T; Roberts TM; Zhao JJ Proc Natl Acad Sci U S A; 2014 Apr; 111(17):6395-400. PubMed ID: 24737887 [TBL] [Abstract][Full Text] [Related]
14. Frequent PTEN loss and differential HER2/PI3K signaling pathway alterations in salivary duct carcinoma: Implications for targeted therapy. Saintigny P; Mitani Y; Pytynia KB; Ferrarotto R; Roberts DB; Weber RS; Kies MS; Maity SN; Lin SH; El-Naggar AK Cancer; 2018 Sep; 124(18):3693-3705. PubMed ID: 30289966 [TBL] [Abstract][Full Text] [Related]
15. Isoform-specific phosphoinositide 3-kinase inhibitors exert distinct effects in solid tumors. Edgar KA; Wallin JJ; Berry M; Lee LB; Prior WW; Sampath D; Friedman LS; Belvin M Cancer Res; 2010 Feb; 70(3):1164-72. PubMed ID: 20103642 [TBL] [Abstract][Full Text] [Related]
16. Increased signalling of EGFR and IGF1R, and deregulation of PTEN/PI3K/Akt pathway are related with trastuzumab resistance in HER2 breast carcinomas. Gallardo A; Lerma E; Escuin D; Tibau A; Muñoz J; Ojeda B; Barnadas A; Adrover E; Sánchez-Tejada L; Giner D; Ortiz-Martínez F; Peiró G Br J Cancer; 2012 Apr; 106(8):1367-73. PubMed ID: 22454081 [TBL] [Abstract][Full Text] [Related]
17. Loss of phosphatase and tensin homolog or phosphoinositol-3 kinase activation and response to trastuzumab or lapatinib in human epidermal growth factor receptor 2-overexpressing locally advanced breast cancers. Dave B; Migliaccio I; Gutierrez MC; Wu MF; Chamness GC; Wong H; Narasanna A; Chakrabarty A; Hilsenbeck SG; Huang J; Rimawi M; Schiff R; Arteaga C; Osborne CK; Chang JC J Clin Oncol; 2011 Jan; 29(2):166-73. PubMed ID: 21135276 [TBL] [Abstract][Full Text] [Related]
18. Dual inhibition of Type I and Type III PI3 kinases increases tumor cell apoptosis in HER2+ breast cancers. Young CD; Arteaga CL; Cook RS Breast Cancer Res; 2015 Dec; 17():148. PubMed ID: 26637440 [TBL] [Abstract][Full Text] [Related]
19. Frequent mutational activation of the PI3K-AKT pathway in trastuzumab-resistant breast cancer. Chandarlapaty S; Sakr RA; Giri D; Patil S; Heguy A; Morrow M; Modi S; Norton L; Rosen N; Hudis C; King TA Clin Cancer Res; 2012 Dec; 18(24):6784-91. PubMed ID: 23092874 [TBL] [Abstract][Full Text] [Related]
20. Targeting PI3K/mTOR overcomes resistance to HER2-targeted therapy independent of feedback activation of AKT. O'Brien NA; McDonald K; Tong L; von Euw E; Kalous O; Conklin D; Hurvitz SA; di Tomaso E; Schnell C; Linnartz R; Finn RS; Hirawat S; Slamon DJ Clin Cancer Res; 2014 Jul; 20(13):3507-20. PubMed ID: 24879796 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]